Encouraging Development of Therapeutics for Neglected Diseases

June 16-17, 2010 • Sheraton Philadelphia City Center Hotel • Philadelphia, PA

Coverage Includes:

• Strategies to Improve Collaboration with Academics
• Ways to Improve the Contributions of Companies in Developing Countries
• Leveraging Opportunities in Developed Markets to Support Neglected Disease Products
• Development of Vaccines, Anti-Virals and Other Anti-Infectives
• Strategies for Sharing Intellectual Property while Still Protecting It
• Best Practices for Collaboration with Developing Countries
• Different Models for Funding and Incentives for Research and Development
• Addressing the Challenge of Delivery in the Face of Limited Health Infrastructure

Cambridge Healthtech Institute
250 First Avenue, Suite 300 • Needham, Massachusetts 02494
Telephone: 781-972-5400 • toll-free in the U.S. 888-999-6288
Fax: 781-972-5425 • www.healthtech.com

healthtech.com/coli
(Package Pricing Available)
There has been a significant increase in the level of activity and attention being paid to the development of therapeutics for neglected diseases over the past five years, but there are still considerable challenges in the road ahead. Diseases in the developed world receive a disproportional investment because of the commercial potential from large markets and the ability to pay for such treatment. Innovative approaches are being developed to stimulate interest and provide incentives for companies and other researchers to work on finding new therapeutics for diseases prevalent in developing countries. Almost all work in this field will be based on collaborations of one type or another, during discovery, drug evaluation or, when successful, delivery of treatments. This forum is designed to bring together many of the major stakeholders addressing these problems, in order to examine and discuss strategies and best practices for solving the major challenges that prevent faster and more effective solutions.

4:15 The Global Health Accelerator: A New Model to Support and Expand Emerging Economies’ Private-Sector Capabilities in Addressing Neglected Diseases
Beatrice Seguin, Ph.D., Assistant Professor, Leslie Dan Faculty of Pharmacy; Program Leader, Commercialization in Emerging Economies McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto
Local solutions to health challenges in the developing world are vital if we are to overcome the neglect of research into diseases affecting the world’s poor. Research has shown that for major pharmaceutical firms, innovation is driven by a combination of the size of a potential market and the income level of a potential market. Since income levels are low in the developing world, most innovation investment by major pharmaceutical firms is targeted at health concerns in the advanced economies where consumers are able to pay prices that ensure a profit. The Global Health Accelerator (GHA) would help Southern firms get their products from the lab to the market. It would create a virtual platform to connect a diverse international community of scientists, entrepreneurs and financiers focused on finding solutions to the diseases of the South, with the added goal of building core strengths, capabilities and companies in the South. The GHA model will be presented.

5:45 Breakout Roundtable Discussions
Discussion Topics Include:
- Creative solutions to intellectual property management, sharing & protection
- Issues related to project financing beyond discovery
- Strategies for aggregating and ensuring demand in developing countries
- Engaging entities in developing countries for research and evaluation
- Strategies for gaining management support for investing in neglected diseases

6:45 Close of Day One

Thursday, June 17

7:15 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

Strategies for Improved Discovery

8:00 Chair’s Remarks

8:05 Summaries from Roundtable Moderators

8:35 A Novel Approach to Drug Development for Neglected Diseases
Dale A. Cumming, Ph.D., Director, Scientific Evaluation, International Consortium on Anti-Virals; Acton Biotech Consulting
The not-for-profit International Consortium on Anti-Virals (ICAV: www.icav-citav.ca), together with its cognate Foundation (the Foundation for Anti-Virals – FAV) represents an innovative spending, drug development and IP management model that harnesses academic discoveries and accelerates their development through to the patient. Encompassing 250 participants from 28 countries, ICAV is focused on a range of neglected, emerging and re-emerging viral diseases. A case study on a Product Development Partnership (PDP) for anti-virals against dengue virus infection will be presented.

Kate Marusina, Ph.D., Manager, Industry Alliances, CTSC, University of California, Davis

The CTSA Pharmaceutical Assets Portal aims to improve information and expertise exchange between pharmaceutical companies and the academic network regarding drugs that may be available for academic repositioning with a specific emphasis on the investigational compounds discontinued at the clinical stages. Via the Portal, CTSA academic community and NIH intramural researchers will be able to match their scientific interests with the repositioning needs of the industry. Integration of the academy into the repositioning efforts would substantially increase the knowledge base and the pool of methodologies available for proof of concept studies. This interaction would undoubtedly result in an increased number of approved drugs for new indications, and thus in considerable public benefit.

9:35 A Model for Research Partnerships to Accelerate Drug Discovery for Neglected Tropical Diseases

Debra Hanna, Ph.D., Senior Principal Scientist, Antibacterial Research Unit, Pfizer, Inc.

A key research need for many of the neglected tropical diseases is quality lead matter for new drug development. Pfizer is leveraging our company's proprietary chemical matter and drug discovery resources with the pathogen biology and disease expertise of a network of external partners to enable screening approaches that prioritize “drugable” new targets. The involvement of post-doctoral scientists from developing countries working in Pfizer’s research laboratories also helps to build capacity for drug discovery research in developing countries.

10:05 Networking Refreshment Break, Poster and Exhibit Viewing

10:45 The Role of the Developing World in Improving R&D Productivity and Efficiency for Neglected Diseases

Rashmi H. Barbhaiya, Ph.D., CEO & Managing Director, Advinus Therapeutics Pvt Ltd, A Tata Enterprise

Return on investment is a key issue for R&D on neglected diseases. Developing countries can provide a cost-effective solution for discovering and developing new medicines. There are a variety of issues, however, that must be addressed in order to create novel and creative collaborative models for discovery of new chemical entities that can serve unmet clinical needs. There is the potential to couple such efforts with public/private partnerships in some developing countries to carry projects forward into full clinical development. There needs to be collaboration between developed and developing countries in order to improve productivity, efficiency and success rates for the R&D effort. In addition, developing countries with the disease burden must have a role in the solution to these global public health issues.

11:15 Leveraging Immunomics: Designing Vaccines for Infectious Diseases and Training Developing World Scientists

Denice Spero, Ph.D., Research Professor & Co-Director, Institute for Immunology and Informatics, University of Rhode Island

The mission of the Institute for Immunology and Informatics (I-Cubed) is to improve human and animal health by applying the power of immunomics (informatics, immunology and genomics) to design better vaccines and therapeutics. A new translational immunology center funded by a 13M dollar NIH U-grant is housed within the I-Cubed and its goal is to accelerate vaccine discovery and development for infectious diseases through the use of immunoinformatics tools. An additional goal is to train scientists from the developing world to use this technology.

11:45 Supporting Healthcare in Developing Countries with Revenues from the Developed World

John Garrett, Ph.D., Co-CEO, Glycosyn, Inc.

Typically, the struggle against endemic, neglected diseases in the developing world has been funded by a small number of charitable organizations: too few organizations with too little money chasing too large and costly problems. Glycosyn is developing a unique, broad-based therapeutic and prophylactic against infectious diarrhea, the largest killer of babies and children in the developing world. We will be funding this work largely through the development, distribution and sale of a wide range of products in the developed world. The strengths and weaknesses of this approach, and how it might be applied to fund work on other major health problems in developing countries, will be presented.

12:15 pm Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Own

Strategies for Discovery and Development

1:45 Chair’s Remarks

1:50 The Role of Multinational Pharmaceutical Companies in Developing and Commercializing Therapies for Diseases with Reduced Profitability

Lydia Pan, Ph.D., Director, Science Policy, Pfizer, Inc.

The pharmaceutical industry has a shared responsibility to conduct research on diseases that disproportionately affect people in the developing world. Whereas individual companies are limited in the ability to solve such universal health problems, multi-sector solutions are needed such as public-private partnerships. These collaborations are essential to making progress on this front, with each partner contributing unique assets and expertise toward the common goal.

2:20 Collaborative Approaches to Facilitating R&D for Neglected Diseases: Navigating the Complex Interface among Diverse Stakeholders

Jacqueline B. Fine, Ph.D., Associate Director, Asset Management and Out-licensing, External Scientific Affairs, Merck Research Laboratories

The challenges we face toward significantly impacting global health, particularly in the developing world, are too complex for any single entity to solve alone. Partnership, as a critical pillar of Merck’s global access strategy will be highlighted, with emphasis on depictions of how robust collaboration among individuals and organizations with diverse backgrounds and capabilities joined together by the mutual goal of improving human health can lead to true innovation. The route to achieving mutual goals may vary from partnership to partnership with respect to specific strategies, targets and needs of the parties; however, we believe the agreements supporting these collaborations should be aligned with current and evolving best practices that include ensuring access on a sustainable basis. A spectrum of activities will be described, from licenses facilitating development of Merck assets for neglected disease indications by public-private partnerships, to a first-of-its-kind joint venture designed to be a sustainable R&D organization that operates like a business— but with a not-for-profit model— aimed at developing new vaccines in areas of unmet need and optimizing existing vaccines for resource-limited settings.

2:50 Open Lab Drug Discovery at GSK for Diseases of the Developing World

Nicholas Carmack, Ph.D., Senior Vice President & Head, Diseases for the Developing World, Medicines Development Campus, GlaxoSmithKline SL (Spain)

GSK’s Open Lab model will be described, including what it is and how it will work. The strategic value of sharing data will be emphasized, particularly as it relates to the benefits for drug discovery for neglected diseases. The question of what are the best models for Pharma companies to collaborate in the area of neglected diseases will also be addressed.

3:20 Networking Refreshment Break, Poster and Exhibit Viewing

3:45 Advanced Vaccine Development for Tropical Disease: Dengue

Gustavo Dayan, Ph.D., Director, Clinical Development, Sanofi Pasteur

Dengue is a mosquito-borne disease that is endemic in some of the world’s most impoverished tropical regions. Dengue affects more than 2.5 billion people, and approximately 90 percent of patients that develop the most severe symptoms are under 15 years old. Currently, the only preventative measures available are individual mosquito protection or mosquito eradication programs, but that is about to change. Experts from Sanofi Pasteur will discuss promising innovations in Dengue vaccine development and the implications for global health.

4:15 Novartis’s Approach to Neglected Diseases in the Developing World: A Malaria Case Study

Brigitta Tadmor, Ph.D., Vice President, Global Head, Diversity & Inclusion and Health Policy, Novartis Institute for BioMedical Research

The Novartis research strategy is driven by medical need and scientific understanding rather than commercial considerations such as market size. This approach enables us to discover and develop medicines for diverse patient populations, including minorities and otherwise underserved groups, as well as people with rare or neglected diseases. This talk focuses on the approach Novartis is taking to address neglected diseases in the developing world, using malaria as an example.

4:45 Improving Treatment of Neglected Diseases in Developing Countries

Prof. Muhammad Yunus, Founder & Managing Director, Gramene Bank; Chairman, Grameen Healthcare Trust; 2006 Nobel Peace Prize Laureate

5:15 Close of Conference
BECOME AN ACTIVE SPONSOR
Your company has a unique opportunity to influence a major gathering of life science executives who will come together at the Encouraging Development of Therapeutics for Neglected Diseases conference. These delegates represent large pharmaceutical and biotechnology companies, academia and national laboratories.
Brand your company as a thought leader by participating as an active Sponsor. Presenting your solutions or services directly to our top-tier delegates can significantly impact their buying decisions and help you achieve your sales and business development objectives.
Opportunities include Agenda, Breakfast and Luncheon Presentations. CHI will support your Sponsorship and brand your company with strong marketing programs before, during and after the event. The earlier you secure your Sponsorship, the more opportunity for exposure.
To explore the ways for your company to participate, please contact:
Arnie Wolfson
Manager, Business Development
Phone: 781-972-5431
Email: awolfson@healthtech.com

Immediatly preceded by

Cambridge Healthtech Institute’s Second Annual
Collaborative Innovation in Biomedicine
June 14-16, 2010 • Sheraton Philadelphia City Center Hotel
Philadelphia, PA

(Package Pricing Available)
healthtech.com/cbi

HOTEL & TRAVEL INFORMATION
Conference Hotel:
Sheraton Philadelphia City Center
17th and Race Streets
Philadelphia, PA 19103
www.Sheraton.com/CityCenter
Phone: 215.448.2000
Fax: 215.448.2864

Discounted Room Rate: $149 s/d
Discounted Cut-off Date: May 18, 2010

Please call the hotel directly to reserve your sleeping accommodations. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the discounted room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

Flight Discounts:
To receive a 5% or greater discount on all American Airline flights please use one of the following methods:
• Call 1-800-433-1790 use Conference code 6360AD
• Go to www.aa.com enter Conference code 6360AD in promotion discount box
• Contact Wendy Levine, Great International Travel 1-800-336-5248 ext. 137

Car Rental Discounts:
Special discount rentals have been established with AVIS for this conference. Please use one of the following methods:
• Call AVIS, 800-331-1600 use our Avis Worldwide Discount (AWD) Number J868190
• Go to www.avis.com use our Avis Worldwide Discount (AWD) Number J868190

MEDIA SPONSORS:
**Encouraging Development of Therapeutics for Neglected Diseases**

**June 16-17, 2010 • Sheraton Philadelphia City Center Hotel • Philadelphia, PA**

### 1. REGISTRATION INFORMATION

REGISTER 3 — 4th IS FREE: Individuals must register for the same conference or conference combination and submit completed registration forms together for discount to apply. Please reproduce this registration form as needed.

<table>
<thead>
<tr>
<th>Name</th>
<th>Job Title</th>
<th>Div./Dept.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Company**
- **Address**
- **City/State/Postal Code**
- **Country**
- **Telephone**
- **Fax**
- **Email**

How would you prefer to receive notices from CHI:  
- EMAIL: ☐ Yes ☐ No  
- FAX: ☐ Yes ☐ No

**POSTER Discount**

Registrations after May 14, 2010 and onsite

**Advance Registration Deadline until May 14, 2010**
- ☐ $1145
- ☐ $475

**Early Registration Discount until March 26, 2010**
- ☐ $1295
- ☐ $545

**Registration after May 14, 2010 and Onsite**
- ☐ $1495
- ☐ $625

---

**2. PRICING INFORMATION**

**ENCOURAGING DEVELOPMENT OF THERAPEUTICS FOR NEGLECTED DISEASES: JUNE 16-17, 2010**

| Early Registration Discount until March 26, 2010 | ☐ $1145 | ☐ $475 |
| Advance Registration Discount until May 14, 2010 | ☐ $1295 | ☐ $545 |

**PACKAGE PRICING – BEST VALUE**

Includes access to two conferences: Collaborative Innovation in Biomedicine (June 14-16) and Encouraging Development of Therapeutics for Neglected Diseases (June 16-17)

- ☐ $1845
- ☐ $795

**Early Registration Deadline until March 26, 2010**
- ☐ $1995
- ☐ $875

**Advance Registration Deadline until May 14, 2010**
- ☐ $2195
- ☐ $945

**Registrations after May 14, 2010 and onsite**
- ☐ $2495
- ☐ $1195

**PRE-CONFERENCE SHORT COURSE: JUNE 14**

- ☐ $595
- ☐ $295

**TRUST BUILDING FOR COLLABORATIVE INNOVATION**

*Separate Registration Required*

**DISCOUNTS**
- ☐ Poster Discount  
- ☐ $50 Off  
- ☐ $50 Off

*Cannot attend but would like to purchase Encouraging Development of Therapeutics for Neglected Diseases conference CD for $350 (plus shipping).*

- ☐ Massachusetts delivery will include sales tax.
- ☐ Please send information on exhibiting and opportunities to present workshops.

**3. PAYMENT INFORMATION**

- ☐ Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.
- ☐ Invoice me, but reserve my space with credit card information listed below. Invoices unpaid two weeks prior to conference will be billed to credit card at full registration rate. Invoices must be paid in full and checks received by the deadline date to retain registration discount. If you plan to register on site, please check with CHI beforehand for space availability.
- ☐ Please charge: ☐ AMEX (15 digits) ☐ Visa (13-16 digits) ☐ MasterCard (16 digits)

**Card #**  
**Exp. Date**

<table>
<thead>
<tr>
<th>Cardholder</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Cardholder’s Address (if different from above)**

<table>
<thead>
<tr>
<th>City/State/Postal Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Please refer to the Registration Code below:**

---

**CHI Insight Pharma Reports**

A series of diverse reports designed to keep life science professionals informed of the salient trends in pharmaceutical technology, business, clinical development, and therapeutic disease markets. For a detailed list of reports, visit [InsightPharmaReports.com](http://www.insightpharmareports.com) or contact Rose LaRaia, rlaraia@healthtech.com, 781-972-5444.

**Barnett Educational Services**

Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit [www.barnettinternational.com](http://www.barnettinternational.com).

---

**Weekly Update**

The latest industry news, commentary and highlights from BioIT World

**eClinica**

Innovative management in clinical trials

**Pharma Services News**

Informatics tools and strategies driving decisions

---

**2010 POSTER AND SAVE $50**

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by May 21, 2010. Register online, or by phone, fax or mail. Indicate that you would like to present a poster and you will receive abstract submission instructions via email.

Yes, I am interested in presenting a poster at  
- Collaborative Innovation in Biomedicine
- Encouraging Development of Therapeutics for Neglected Diseases

**Title**

---

**Additional Registration Details**

- Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.
- **Group Discounts**
- Special rates are available for multiple attendees from the same organization. Contact David Cunningham at 781-972-5472 to discuss your options and take advantage of the savings.
- **Handicapped Equal Access**
- In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.
- **Substitution/Cancellation Policy**
- In the event that you need to cancel a registration, you may:
  - Transfer your registration to a colleague within your organization
  - Credit your registration to another Cambridge Healthtech Institute program.
  - Request a refund minus a $100 processing fee per conference.
  - Request a refund minus the cost ($350) of ordering a copy of the CD.
- **NOTE:** Cancellations will only be accepted up to two weeks prior to the conference.

Program and speakers are subject to change.

Video and or audio recording of any kind is prohibited onsite at all CHI events.